Clinical Trials Directory

Trials / Completed

CompletedNCT01638663

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)

Effect of Vasopressin Antagonism on Renal Sodium and Water Handling and Circulation During Inhibition of the Nitric Oxide System in Healthy Subjects

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Regional Hospital Holstebro · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to investigate the effect of tolvaptan on renal water, sodium and potassium excretion, plasma concentration of vasoactive hormones,central blood pressure, pulse wave velocity (PWV) and augmentation index, basal and during inhibition of nitric oxide synthesis in healthy subjects.

Detailed description

Tolvaptan is a vasopressin antagonist (V2-antagonist) and is used in treatment of hyponatremia. Animal studies have demonstrated that inhibition of V2 receptors in the renal principal cell increases renal free water clearance and renal sodium excretion. Treatment with V2-receptor antagonists increases vasopressin concentration in plasma that stimulates V1-receptors in the vascular bed. This may change both central and peripheral hemodynamics and plasma concentration of vasoactive hormones. Changes in hemodynamics and hormone concentration may consequently change renal sodium and water handling. The nitric oxide system plays a central role in both renal sodium and water handling and regulation of vascular tone and blood pressure. The effects of tolvaptan the circulation and kidneys is investigated by using measurements of biomarkers specific for the sodium/water balance in the urine and by measurements of vasoactive hormones in the blood after administration of tolvaptan and L-NMMA infusion.

Conditions

Interventions

TypeNameDescription
DRUGTolvaptan15 mg pr day for 1 day
DRUGPlacebo1 tablet Unikalk 1 pr day for 1 day

Timeline

Start date
2012-05-01
Primary completion
2014-03-01
Completion
2014-03-01
First posted
2012-07-12
Last updated
2014-10-09

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01638663. Inclusion in this directory is not an endorsement.